ABBV-706 (NCT07155174)

Name: ABBV-706 trial for Small Cell Lung Cancer (NCT07155174)
Uploaded: 2026-10-31T05:34:00.004Z
Duration: 1 min 20 s
Description: ABBV-706 trial for Small Cell Lung Cancer (NCT07155174). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07155174.

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer: a one-minute explainerNCT071551741 min

ABBV-706 trial for Small Cell Lung Cancer (NCT07155174). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with previously untreated extensive-stage small-cell lung cancer. Previous treatment for limited-stage disease and active or symptomatic brain metastases exclude participation.

The idea: compare two doses of intravenous ABBV-706 plus atezolizumab against carboplatin, etoposide and atezolizumab, with optional lurbinectedin. ABBV-706 delivers a toxic payload to SEZ6-bearing cells; atezolizumab blocks an immune brake. A safety lead-in precedes expansion; researchers compare progression and side effects.

This phase 2 study plans 180 patients. AbbVie sponsors it; 12 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.